RNA therapy for polyglutamine neurodegenerative diseases

Expert Reviews in Molecular Medicine

Volumn 14, Issue , 2012, Pages

  Watson, Lauren M ^a,b   Wood, Matthew J A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LENTIVIRUS VECTOR; LOCKED NUCLEIC ACID; MICRORNA; MUTANT PROTEIN; PROTEASOME; RNA INDUCED SILENCING COMPLEX; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; PEPTIDE; POLYGLUTAMINE; RNA;

ANDROGEN RECEPTOR GENE; ANTISENSE THERAPY; ATN1 GENE; ATXN1 GENE; ATXN2 GENE; ATXN3 GENE; ATXN7 GENE; CACNA1A GENE; CAG REPEAT; DEGENERATIVE DISEASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DUCHENNE MUSCULAR DYSTROPHY; GENE; GENE FREQUENCY; GENE REPLACEMENT THERAPY; GENE SILENCING; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; HTT GENE; HUMAN; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRIAL GENOME; MOLECULAR PATHOLOGY; NEUROPROTECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POLYGLUTAMINE NEURODEGENERATIVE DISEASE; PRIORITY JOURNAL; PROTEIN PROCESSING; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TBP GENE; THERAPY EFFECT; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; GENETICS; METABOLISM; METHODOLOGY; TRINUCLEOTIDE REPEAT;

ANIMALS; GENE SILENCING; GENE THERAPY; HUMANS; NEURODEGENERATIVE DISEASES; PEPTIDES; RNA; TRINUCLEOTIDE REPEATS;

EID: 84859024380     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/erm.2011.1     Document Type: Review

References (165)

1. Durr, A. (2010) Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurology 9, 885-894
2. SteVanin, G. et al. (1998) De novo expansion of intermediate alleles in spinocerebellar ataxia 7. Human Molecular Genetics 7, 1809-1813
3. Garden, G.A. and La Spada, A.R. (2007) Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration. Cerebellum 99999, 1-12
4. Globas, C. et al. (2008) Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. Movement Disorders 23, 2232-2238
5. Lebre,A.S.andBrice,A. (2003) Spinocerebellar ataxia 7(SCA7). CytogeneticGenomeResearch100, 154-163
6. Pulst, S.M. et al. (2005) Spinocerebellar ataxia type 2: polyQ repeat variation in the CACNA1A calcium channel modifies age of onset. Brain 128, 2297-2303
7. Li, S.H. and Li, X.J. (2004) Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends in Genetics 20, 146-154
8. Saegusa, H. et al. (2007) Properties of human Cav2. 1 channel with a spinocerebellar ataxia type 6 mutation expressed in Purkinje cells. Molecular and Cellular Neuroscience 34, 261-270 (Pubitemid 46137001)
9. La Spada, A.R. et al. (2001) Polyglutamineexpanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron 31, 913-927 (Pubitemid 32925279)
10. Helmlinger, D. et al. (2006) Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biology 4, 432-445
11. Yoo, S.Y. et al. (2003) SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron 37, 383-401
12. Bichelmeier, U. et al. (2007) Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. Journal of Neuroscience 27, 7418-7428 (Pubitemid 47066563)
13. Burright, E.N. et al. (1995) SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82, 937-948
14. Goti, D. et al. (2004) A mutant ataxin-3 putativecleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. Journal of Neuroscience 24, 10266-10279 (Pubitemid 39492054)
15. Watase, K. et al. (2002) A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34, 905-919 (Pubitemid 34722281)
16. Huynh, D.P. et al. (2003) Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. Human Molecular Genetics 12, 1485-1496 (Pubitemid 36857297)
17. Cemal, C.K. et al. (2002) YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Human Molecular Genetics 11, 1075-1094 (Pubitemid 34521089)
18. Shirendeb, U. et al. (2011) Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Human Molecular Genetics 20, 1438-1455
19. Yamanaka, T. and Nukina, N. (2010) Transcription factor sequestration by polyglutamine proteins. Methods in Molecular Biology (Clifton, NJ) 648, 215-229
20. Sugars, K.L. and Rubinsztein, D.C. (2003) Transcriptional abnormalities in Huntington disease. Trends in Genetics 19, 233-238 (Pubitemid 36511427)
21. Einum, D.D. et al. (2001) Ataxin-7 expression analysis in controls and spinocerebellar ataxia type 7 patients. Neurogenetics 3, 83-90 (Pubitemid 33738398)
22. Carlson, K.M., Andresen, J.M. and Orr, H.T. (2009) Emerging pathogenic pathways in the spinocerebellar ataxias. Current Opinion in Genetics and Development 19, 247-253
23. Duenas, A.M., Goold, R. and Giunti, P. (2006) Molecular pathogenesis of spinocerebellar ataxias. Brain 129, 1357-1370 (Pubitemid 43999370)
24. Shao, J. and Diamond, M.I. (2007) Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Human Molecular Genetics 16, R115-R123
25. Palhan, V.B. et al. (2005) Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proceedings of theNational Academyof Sciences of the United States of America 102, 8472-8477 (Pubitemid 40862760)
26. Zoghbi, H.Y. and Orr, H.T. (2009) Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. Journal of Biological Chemistry 284, 7425-7429
27. Kim, M.O. et al. (2008) Altered histone monoubiquitylation mediated by mutant huntingtin induces transcriptional dysregulation. Journal of Neuroscience 28, 3947-3957
28. Yvert, G. et al. (2001) SCA7 mouse models show selective stabilization of mutant ataxin-7 and similar cellular responses in different neuronal cell types. Human Molecular Genetics 10, 1679-1692 (Pubitemid 32776298)
29. Young, J.E. et al. (2009) Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk. Journal of Neuroscience 29, 1987-1997
30. Colomer Gould, V.F. et al. (2007) A mutant ataxin-3 fragment results from processing at a site Nterminal to amino acid 190 in brain of Machado- Joseph disease-like transgenic mice. Neurobiology of Disease 27, 362-369 (Pubitemid 47337189)
31. Jung, J. et al. (2009) Preventing ataxin-3 protein cleavage mitigates degeneration in a drosophila model of SCA3. Human Molecular Genetics 18, 4843-4852
32. Landles, C. et al. (2010) Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. Journal of Biological Chemistry 285, 8808-8823
33. Clemens, L.E. et al. (2010) A14 fast axonal transport of mitochondria is altered in Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry 81, A5
34. Bennett, E.J. et al. (2007) Global changes to the ubiquitin system in Huntington's disease. Nature 448, 704-708 (Pubitemid 47236860)
35. Bence, N.F., Sampat, R.M. and Kopito, R.R. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555 (Pubitemid 32493425)
36. Jana, N.R. (2010) Role of the ubiquitin-proteasome system and autophagy in polyglutamine neurodegenerative diseases. Future Neurology 5, 105-112
37. Drouet,V. et al. (2009) Sustained effects of nonallelespecific Huntingtin silencing. Annals of Neurology 65, 276-285
38. Boudreau, R.L. and Davidson, B.L. (2010) RNAi therapeutics for CNS disorders. Brain Research 1338, 112-121
39. Hasholt, L. et al. (2003) Antisense downregulation of mutant huntingtin in a cell model. Journal of Gene Medicine 5, 528-538 (Pubitemid 40310396)
40. Bauer, P.O. and Nukina, N. (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. Journal of Neurochemistry 110, 1737-1765
41. Xia, H. et al. (2002) siRNA-mediated gene silencing in vitro and in vivo. Nature Biotechnology 20, 1006-1010
42. Yamamoto, A., Lucas, J.J. and Hen, R. (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57-66
43. Zu, T. et al. (2004) Recovery from polyglutamineinduced neurodegeneration in conditional SCA1 transgenic mice. Journal of Neuroscience 24, 8853-8861 (Pubitemid 39362981)
44. Rodriguez-Lebron, E. and Paulson, H.L. (2005) Allele-specific RNA interference for neurological disease. Gene Therapy 13, 576-581
45. Scholefield, J. andWood, M.J.A. (2010) Therapeutic gene silencing strategies for polyglutamine disorders. Trends in Genetics 26, 29-38
46. Kubodera, T. et al. (2010) In vivo application of an RNAi strategy for the selective suppression of a mutant allele. Human Gene Therapy 22, 27-34
47. Kubodera, T. et al. (2005) New RNAi strategy for selective suppression of a mutant allele in polyglutamine disease. Oligonucleotides 15, 298-302 (Pubitemid 43108226)
48. Nasir, J. et al. (1995) Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81, 811-823
49. Dragatsis, I., Levine, M.S. and Zeitlin, S. (2000) Inactivation of hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nature Genetics 26, 300-306
50. Van Raamsdonk, J.M. et al. (2005) Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Human Molecular Genetics 14, 1379-1392 (Pubitemid 40744495)
51. Persichetti, F. et al. (1996) Differential expression of normal and mutant Huntington's disease gene alleles. Neurobiology of Disease 3, 183-190 (Pubitemid 26391321)
52. Ambrose, C.M. et al. (1994) Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somatic Cell and Molecular Genetics 20, 27-38 (Pubitemid 24161062)
53. Matilla, A. et al. (1998) Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation. Journal of Neuroscience 18, 5508-5516 (Pubitemid 28311965)
54. Jun, K. et al. (1999) Ablation of P/Q-type Ca2 channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the a1Asubunit. Proceedings of the National Academy of Sciences of the United States of America 96, 15245-15250 (Pubitemid 30019797)
55. Crespo-Barreto, J. et al. (2010) Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis. PLoS Genetics 6, 575-621
56. Lim, J. et al. (2008) Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 452, 713-718 (Pubitemid 351521076)
57. Warrick, J.M. et al. (2005) Ataxin-3 suppresses polyglutamine neurodegeneration in drosophila by a ubiquitin-associated mechanism. Molecular Cell 18, 37-48 (Pubitemid 40444646)
58. Schmitt, I. et al. (2007) Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochemical and Biophysical Research Communications 362, 734-739 (Pubitemid 47368155)
59. Figueroa, K.P. and Pulst, S.M. (2003) Identification and expression of the gene for human ataxin-2- related protein on chromosome 16. Experimental Neurology 184, 669-678 (Pubitemid 38185824)
60. Shen, Y. et al. (2007) Functional architecture of atrophins. Journal of Biological Chemistry 282, 5037-5044 (Pubitemid 47100924)
61. Rooms, L. et al. (2006) TBP as a candidate gene for mental retardation in patients with subtelomeric 6q deletions. European Journal of Human Genetics 14, 1090-1096 (Pubitemid 44463967)
62. Yeh, S. et al. (2002) Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proceedings of the National Academy of Sciences of the United States of America 99, 13498-13503 (Pubitemid 35215410)
63. Wang, R.S. et al. (2009) Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice. Endocrine Reviews 30, 119-132
64. Weinberg, M.S. andWood, M.J.A. (2009) Short noncoding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics. Human Molecular Genetics 18, R27-R39
65. Zamore, P.D. et al. (2000) RNAi:: double-stranded RNAdirects theATP-dependent cleavage ofmRNA at 21 to 23 nucleotide intervals. Cell 101, 25-33
66. Castanotto, D. and Rossi, J.J. (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457, 426-433
67. Boudreau, R.L., Monteys, A.M. and Davidson, B.L. (2008) Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 14, 1834-1844
68. Grimm, D. et al. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (Pubitemid 44050158)
69. Boudreau, R.L., Martins, I. and Davidson, B.L. (2008) Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Molecular Therapy 17, 169-175
70. DenoVan-Wright, E.M. et al. (2008) Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo. Neurobiology of Disease 29, 446-455
71. Bauer, M. et al. (2008) Prevention of interferonstimulated gene expression using microRNAdesigned hairpins. Gene Therapy 16, 142-147
72. McBride, J.L. et al. (2008) Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proceedings of the National Academy of Sciences of the United States of America 105, 5868-5873 (Pubitemid 351758464)
73. Smith, R.A. et al. (2006) Antisense oligonucleotide therapy for neurodegenerative disease. Journal of Clinical Investigation 116, 2290-2296 (Pubitemid 44162339)
74. Crooke, S.T. (2004) Progress in antisense technology. Annual Review of Medicine 55, 61-95 (Pubitemid 38316716)
75. Gagnon, K.T. et al. (2010) Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 49, 10166-10178
76. Boudreau, R.L. et al. (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Molecular Therapy 17, 1053-1063
77. Harper, S.Q. et al. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proceedings of the National Academy of Sciences of the United States of America 102, 5820-5825 (Pubitemid 40559643)
78. Caplen, N.J. et al. (2002) Rescue of polyglutaminemediated cytotoxicity by double-stranded RNAmediated RNA interference. Human Molecular Genetics 11, 175-184 (Pubitemid 34157009)
79. Xia, H. et al. (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nature Medicine 10, 816-820 (Pubitemid 39070854)
80. Boado, R.J. et al. (2000) Antisense-mediated downregulation of the human huntingtin gene. Journal of Pharmacology and Experimental Therapeutics 295, 239-243
81. Rodriguez-Lebron, E. et al. (2005) Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Molecular Therapy 12, 618-633 (Pubitemid 41350143)
82. Franich, N.R. et al. (2008) AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Molecular Therapy 16, 947-956 (Pubitemid 351587106)
83. Machida, Y. et al. (2006) rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochemical and Biophysical Research Communications 343, 190-197
84. Alves, S. et al. (2010) Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? Human Molecular Genetics 19, 2380-2394
85. Abdelgany, A., Wood, M. and Beeson, D. (2003) Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference. Human Molecular Genetics 12, 2637-2644 (Pubitemid 37304686)
86. Gonzalez-Alegre, P. et al. (2003) Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA. Annals of Neurology 53, 781-787 (Pubitemid 36622516)
87. Xia, X. et al. (2006) Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiology of Disease 23, 578-586 (Pubitemid 44234094)
88. Schwarz, D.S. et al. (2006) Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genetics 2, e140
89. Bilsen, P.H.J. et al. (2008) Identification and allelespecific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Human Gene Therapy 19, 710-718 (Pubitemid 352009910)
90. Pfister, E.L. et al. (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Current Biology 19, 774-778
91. Ohnishi, Y. et al. (2008) Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi. PloS One 3, e2248
92. Lombardi, M.S. et al. (2009) A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Experimental Neurology 217, 312-319
93. Zhang, Y., Engelman, J. and Friedlander, R.M. (2009) Allele-specific silencing of mutant Huntington's disease gene. Journal of Neurochemistry 108, 82-90
94. Li, Y. et al. (2004) Sequence-dependent and independent inhibition specific for mutant ataxin-3 by small interfering RNA. Annals of Neurology 56, 124-129 (Pubitemid 38857368)
95. Gaspar, C. et al. (1996) Linkage disequilibrium analysis in Machado-Joseph disease patients of different ethnic origins. Human Genetics 98, 620-624 (Pubitemid 26394846)
96. Miller, V.M. et al. (2003) Allele-specific silencing of dominant disease genes. Proceedings of the National Academy of Sciences of the United States of America 100, 7195-7200 (Pubitemid 36706415)
97. Alves, S. et al. (2008) Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 3, e3341
98. Scholefield, J. et al. (2009) Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. PLoS One 4, e7232
99. Cattaneo, E. et al. (2001) Loss of normal huntingtin function: new developments in Huntington's disease research. Trends in Neurosciences 24, 182-188 (Pubitemid 32166824)
100. Hu, J., Matsui, M. and Corey, D.R. (2009) Alleleselective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Annals of the New York Academy of Sciences 1175, 24-31
101. Kastelein, J.J.P. et al. (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729-1735 (Pubitemid 44607121)
102. Sah, D.W.Y. and Aronin, N. (2011) Oligonucleotide therapeutic approaches for Huntington disease. Journal of Clinical Investigation 121, 500-507
103. Hu, J., Liu, J. and Corey, D.R. (2010) Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chemistry and Biology 17, 1183-1188
104. Kim, D.H. and Rossi, J.J. (2003) Coupling of RNAimediated target downregulation with gene replacement. Antisense and Nucleic Acid Drug Development 13, 151-155
105. Kim, D.H. et al. (2008) MicroRNA-directed transcriptional gene silencing in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America 105, 16230-16235
106. Younger, S.T. and Corey, D.R. (2011) Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters. Nucleic Acids Research 39, 5682-5691
107. Hawkins, P.G. et al. (2009) Promoter targeted small RNAs induce long-term transcriptional gene silencing inhumancells. Nucleic Acids Research 37, 2984-2995
108. Morris, K.V. et al. (2008) Bidirectional transcription directs both transcriptional gene activation and suppression in human cells. PLoS Genetics 4, e1000258
109. Han, J., Kim, D. and Morris, K.V. (2007) Promoter-associated RNA is required for RNAdirected transcriptional gene silencing in human cells. Proceedings of the National Academy of Sciences of the United States of America 104, 12422-12427 (Pubitemid 47206153)
110. Li, L.B. et al. (2008) RNA toxicity is a component of ataxin-3 degeneration in drosophila. Nature 453, 1107-1111
111. de Mezer, M. et al. (2011) Mutant CAG repeats of huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference. Nucleic Acids Research 39, 3852-3863
112. Wheeler, T.M. et al. (2009) Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325, 336-339
113. Todd, P.K. and Paulson, H.L. (2010) RNA-mediated neurodegeneration in repeat expansion disorders. Annals of Neurology 67, 291-300
114. Dickson, A.M. and Wilusz, C.J. (2010) Repeat expansion diseases: when a good RNA turns bad. Wiley Interdisciplinary Reviews - RNA 1, 173-192
115. Roshan, R. et al. (2009) MicroRNAs: novel therapeutic targets in neurodegenerative diseases. Drug Discovery Today 14, 1123-1129
116. Johnson, R. et al. (2007) A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiology of Disease 29, 438-445
117. Lee, Y. et al. (2008) miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nature Neuroscience 11, 1137-1139
118. Lundstrom, K. (2011) Micro-RNA in disease and gene therapy. Current Drug Discovery Technologies 8, 76-86
119. Bilen, J., Liu, N. and Bonini, N.M. (2006)A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins. Cell Cycle 5, 2835-2838 (Pubitemid 44953931)
120. Schaefer, A. et al. (2007) Cerebellar neurodegeneration in the absence of microRNAs. Journal of Experimental Medicine 204, 1553-1558 (Pubitemid 47048023)
121. Giraldez, A.J. et al. (2005) MicroRNAs regulate brain morphogenesis in zebrafish. Science 308, 833-838 (Pubitemid 40629259)
122. Lesnik, J.K. and Antes, T.J. (2010) Permanent knockdown of microRNAs using lentivectors. BioTechniques 48, 321-323
123. Lennox, K. and Behlke, M. (2011) Chemical modification and design of anti-miRNA oligonucleotides. Gene Therapy 18, 1111-1120
124. Elmén, J. et al. (2008) LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899 (Pubitemid 351550859)
125. Obad, S. et al. (2011) Silencing of microRNA families by seed-targeting tiny LNAs. Nature Genetics 43, 371-378
126. Worm, J. et al. (2009) Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp beta and downregulation of G-CSF. Nucleic Acids Research 37, 5784-5792
127. Jadhav, V.M., Scaria, V. and Maiti, S. (2009) Antagomirzymes: oligonucleotide enzymes that specifically silence microRNA function. Angewandte Chemie International Edition 48, 2557-2560
128. Broderick, J.A. and Zamore, P.D. (2011) MicroRNA therapeutics. Gene Therapy adVance online publication, 28 April 2011; doi:10.1038/ gt.2011.50
129. Cao, W. et al. (2005) DNA constructs designed to produce short hairpin, interfering RNAs in transgenic mice sometimes showearly lethality and an interferon response. Journal of Applied Genetics 46, 217-225 (Pubitemid 40840277)
130. Sledz, C.A. et al. (2003) Activation of the interferon system by short-interfering RNAs. Nature Cell Biology 5, 834-839 (Pubitemid 37087172)
131. Jackson, A.L. and Linsley, P.S. (2010) Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nature Reviews Drug Discovery 9, 57-67
132. Jackson, A.L. et al. (2003) Expression profiling reveals off-target gene regulation by RNAi. Nature Biotechnology 21, 635-637 (Pubitemid 36638089)
133. Jackson, A.L. et al. (2006) Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12, 1179-1187 (Pubitemid 43990543)
134. Persengiev, S.P., Zhu, X. and Green, M.R. (2004) Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10, 12-18 (Pubitemid 38018731)
135. Naito, Y. et al. (2004) siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference. Nucleic Acids Research 32 (Suppl. 2), W124-W129 (Pubitemid 38997313)
136. Kittler, R. et al. (2007) Genome-wide resources of endoribonuclease- prepared short interferingRNAs for specific loss-of-function studies. Nature Methods 4, 337-344 (Pubitemid 46766979)
137. Bramsen, J.B. et al. (2010) A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Research 38, 5761-5773
138. Fedorov, Y. et al. (2006) Off-target effects by siRNA can induce toxic phenotype. RNA 12, 1188-1196 (Pubitemid 43990544)
139. Jackson, A.L. et al. (2006) Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12, 1197-1205 (Pubitemid 43990545)
140. Hornung, V. et al. (2005) Sequence-specific potent induction of IFN-a by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature Medicine 11, 263-270 (Pubitemid 40460553)
141. Judge, A.D. et al. (2006) Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Molecular Therapy 13, 494-505 (Pubitemid 43257617)
142. Sioud, M. (2005) Induction of inflammatory cytokines and interferon responses by doublestranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. Journal of Molecular Biology 348, 1079-1090 (Pubitemid 40602367)
143. Kleinman, M.E. et al. (2008) Sequence-and targetindependent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-597 (Pubitemid 351483358)
144. Khan, A.A. et al. (2009) Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nature Biotechnology 27, 549-555
145. Dessy, A. and Gorman, J.M. (2011) The emerging therapeutic role of RNA interference in disorders of the central nervous system. Clinical Pharmacology and Therapeutics 89, 450-454
146. Eberling, J.L. et al. (2008) Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70, 1980-1983
147. Naldini, L. et al. (1996) Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proceedings of the National Academy of Sciences of the United States of America 93, 11382-11388 (Pubitemid 26347130)
148. Dorn, G. et al. (2004) siRNA relieves chronic neuropathic pain. Nucleic Acids Research 32, e49
149. Alvarez-Erviti, L. et al. (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnology 29, 341-345
150. Agrawal, A. et al. (2009) Functional delivery of siRNA in mice using dendriworms. ACS Nano 3, 2495-2504
151. Luo, M.C. et al. (2005) An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Molecular Pain 1, 29-36
152. Vaishnaw, A.K. et al. (2010)Astatus report on RNAi therapeutics. Silence 1, 1-13
153. Cattaneo, E., Zuccato, C. and Tartari, M. (2005) Normal huntingtin function: an alternative approach to Huntington's disease. Nature Reviews Neuroscience 6, 919-930 (Pubitemid 41753086)
154. Wang, L. et al. (2006) Histone deacetylaseassociating atrophin proteins are nuclear receptor corepressors. Genes and Development 20, 525-530 (Pubitemid 43345318)
155. Goold, R. et al. (2007) Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1. Human Molecular Genetics 16, 2122-2134 (Pubitemid 47354895)
156. Ralser, M. et al. (2005) An integrative approach to gain insights into the cellular function of human ataxin-2. Journal of Molecular Biology 346, 203-214 (Pubitemid 40128315)
157. Kiehl, T.R. et al. (2006) Generation and characterization of Sca2 (ataxin-2) knockout mice. Biochemical and Biophysical Research Communications 339, 17-24
158. Huynh, D.P. et al. (2009) Dissociated fearand spatial learning in mice with deficiency of ataxin-2. PloS One 4, e6235
159. Evert, B.O. et al. (1999) High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells. Human Molecular Genetics 8, 1169-1176 (Pubitemid 29328984)
160. Helmlinger, D. et al. (2004) Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Human Molecular Genetics 13, 1257-1265 (Pubitemid 38877879)
161. Shah, A.G. et al. (2009) Transcriptional dysregulation of TrkA associates with neurodegeneration in spinocerebellar ataxia type 17. Human Molecular Genetics 18, 4141-4152
162. Van Roon-Mom,W.M.C. et al. (2005) TATA-binding protein in neurodegenerative disease. Neuroscience 133, 863-872 (Pubitemid 40814595)
163. Zimmermann, T.S. et al. (2006) RNAi-mediated gene silencing in non-human primates. Nature 441, 111-114
164. Henry, S. et al. (2000) Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. Journal of Pharmacology and Experimental Therapeutics 292, 468-479 (Pubitemid 30067408)
165. Kunze, D., Kraemer, K. and Fuessel, S. (2010) Antisense oligonucleotides: insights from preclinical studies and clinical trials. In RNA Technologies and their Applications (Erdmann, V.A. and Barciszewski, J., eds), pp. 285-303, Springer, Berlin Heidelberg